ATE326222T1 - Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch - Google Patents

Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Info

Publication number
ATE326222T1
ATE326222T1 AT01920377T AT01920377T ATE326222T1 AT E326222 T1 ATE326222 T1 AT E326222T1 AT 01920377 T AT01920377 T AT 01920377T AT 01920377 T AT01920377 T AT 01920377T AT E326222 T1 ATE326222 T1 AT E326222T1
Authority
AT
Austria
Prior art keywords
naltrexone
naloxone
treatment
analogs
pain
Prior art date
Application number
AT01920377T
Other languages
English (en)
Inventor
Wolfgang Sadee
Danxin Wang
Original Assignee
Wolfgang Sadee
Danxin Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22697044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326222(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wolfgang Sadee, Danxin Wang filed Critical Wolfgang Sadee
Application granted granted Critical
Publication of ATE326222T1 publication Critical patent/ATE326222T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01920377T 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch ATE326222T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18937200P 2000-03-15 2000-03-15

Publications (1)

Publication Number Publication Date
ATE326222T1 true ATE326222T1 (de) 2006-06-15

Family

ID=22697044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920377T ATE326222T1 (de) 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Country Status (7)

Country Link
US (2) US20010049375A1 (de)
EP (1) EP1263438B1 (de)
AT (1) ATE326222T1 (de)
AU (1) AU4743601A (de)
CA (1) CA2403252A1 (de)
DE (1) DE60119696T2 (de)
WO (1) WO2001068080A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
PT2425824T (pt) 2002-04-05 2017-08-23 Mundipharma Farmacêutica Lda Preparação farmacêutica contendo oxicodona e naloxona
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
DE602004012403T2 (de) * 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
NZ583573A (en) * 2003-12-16 2011-12-22 Nektar Therapeutics Pegylated naloxol
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20070197573A1 (en) * 2005-10-04 2007-08-23 Wolfgang Sadee Compositions and methods in the treatment of bone metabolic disorders
PL2135603T3 (pl) * 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
CN1813740B (zh) * 2005-11-22 2010-05-05 岳振江 一种含有盐酸纳洛酮的舌下膜剂及其制备方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
EP2089005B1 (de) 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008136995A1 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Polymorphisms in genes affecting dopamine transporter disorders and uses thereof
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ME03298B (de) 2009-03-10 2019-07-20 Euro Celtique Sa Oxycodon und naloxon enthaltende pharmazeutische zusammensetzung mit sofortiger freisetzung
JP6196041B2 (ja) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
WO2011139525A1 (en) * 2010-05-05 2011-11-10 Philadelphia Health & Education Corporation Stereoisomer of naloxone and potential therapeutic action of opioid drugs to reverse clinical tolerance to these agents
ES2632932T3 (es) * 2010-10-19 2017-09-18 Memorial Sloan-Kettering Cancer Center Derivados 6-amido de 4,5a-epoximorfinanos para el tratamiento del dolor
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans
CN105517551A (zh) 2013-07-23 2016-04-20 欧洲凯尔特公司 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
WO2015184059A1 (en) 2014-05-30 2015-12-03 The Research Foundation For The State University Of New York Compositions and methods to promote bone formation
CA3241654A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3400066B1 (de) 2016-01-08 2021-07-28 Ohio State Innovation Foundation Behandlungen und vorbeugung des neonatalen opioidabstinenzsyndroms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3083850A1 (en) 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2020205097A1 (en) * 2019-01-04 2021-07-15 Aether Therapeutics Inc. Method for treating drug or alcohol dependency
EP3934647A1 (de) * 2019-03-06 2022-01-12 LDN Pharma Limited Verfahren zur bestimmung der wirksamkeit
JP2022541452A (ja) 2019-07-15 2022-09-26 ロバクサ がんの治療のための方法および組成物
CA3186145A1 (en) 2020-07-17 2022-01-20 Bryan S. MARGULIES Methods and compositions to graft bone using iron excipients
US20240325379A1 (en) * 2021-07-06 2024-10-03 Aether Therapeutics Inc. Low-dose naltrexol and uses thereof
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
US12403118B1 (en) 2025-03-05 2025-09-02 Zetagen Therapeutics, Inc. Cancer treatments using modified fatty acids and the carriers to administer them

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254088A (en) 1961-03-14 1966-05-31 Lewenstein Morphine derivative
NL137652C (de) 1962-07-11
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (de) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4816586A (en) 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5051426A (en) 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
CH683005A5 (it) * 1991-10-30 1993-12-31 Aldo Massarotti Procedimento per la preparazione, mediante ossidazione di N-ossidi per le terapie dei tossicomani da oppiati.
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US6007986A (en) 1993-06-23 1999-12-28 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic activity screening
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
WO1996014071A1 (es) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combinacion de farmacos como medicamento destinado a supresion de dependencia de individuos a opiaceos
DK0814843T3 (da) 1995-03-31 2004-03-29 Xenova Res Ltd Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
EP0828489A4 (de) * 1996-03-13 2001-04-04 Univ Yale Raucherentwöhnungsbehandlung unter verwendung von naltrexon und verwandten verbindungen
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5760044A (en) * 1996-05-16 1998-06-02 Archer; Sydney Method for treating cocaine and amphetamine dependency
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
EP1011671A1 (de) * 1997-05-20 2000-06-28 Yale University Entwöhnungstherapie mit opiat- und serotoninantagonisten
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion

Also Published As

Publication number Publication date
WO2001068080A3 (en) 2002-07-04
US20030069262A1 (en) 2003-04-10
US6713488B2 (en) 2004-03-30
EP1263438B1 (de) 2006-05-17
DE60119696T2 (de) 2007-01-25
US20010049375A1 (en) 2001-12-06
WO2001068080A2 (en) 2001-09-20
DE60119696D1 (de) 2006-06-22
AU4743601A (en) 2001-09-24
CA2403252A1 (en) 2001-09-20
EP1263438A2 (de) 2002-12-11

Similar Documents

Publication Publication Date Title
ATE326222T1 (de) Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
WO2004017941A3 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
CA2302754A1 (en) Noribogaine in the treatment of pain and drug addiction
NO20001175D0 (no) Smertestillende blandinger omfattende anti-epileptiske forbindelser og fremgangsmÕter for anvendelse derav
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
KR970009799A (ko) 물질 남용 금단의 치료 방법
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
WO2001091736A3 (en) Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
NO20060913L (no) Behandling av avhengighetsabstinens
ES2253662T3 (es) Procedimiento de tratamiento de un paciente que requiere analgesia.
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
JP7244992B2 (ja) オピオイドとｎ－アシルエタノールアミンの組み合わせ
Komoda et al. Enhancement of lidocaine-induced epidural anesthesia by deoxyaconitine in the rabbit
WO2007059445A3 (en) Synergistic combinations of norketamine and opioid analgesics
d'Amours et al. Perioperative drugs and postoperative pain management
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
US20040198723A1 (en) Method of treatment
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
MD1610F1 (en) Method of the recidivating chronic aphthous stomatitis treatment
Hanks Current Availability and Use of Morphine in Developed Countries and Relevance of Alternative Opioids to Morphine in Clinical Practice

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties